Kazufumi Nakamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1842534/publications.pdf

Version: 2024-02-01

105 papers 3,272 citations

172457 29 h-index 53 g-index

108 all docs

108 docs citations

108 times ranked 4359 citing authors

#	Article	IF	CITATIONS
1	Incremental prognostic value of non-alcoholic fatty liver disease over coronary computed tomography angiography findings in patients with suspected coronary artery disease. European Journal of Preventive Cardiology, 2022, 28, 2059-2066.	1.8	22
2	Fragmented QRS as a predictor of cardiac events in patients with cardiac sarcoidosis. Journal of Cardiology, 2022, 79, 446-452.	1.9	5
3	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 3587.	4.1	48
4	Enhancement of pacing function by HCN4 overexpression in human pluripotent stem cell-derived cardiomyocytes. Stem Cell Research and Therapy, 2022, 13, 141.	5. 5	3
5	Molecular Mechanisms of Cardiac Amyloidosis. International Journal of Molecular Sciences, 2022, 23, 25.	4.1	20
6	LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats. Scientific Reports, 2022, 12, 4930.	3.3	10
7	Innovative clinical pathway shortened the length of hospital stay and prevented readmission in patients with acute decompensated heart failure. Journal of Cardiology, 2022, 80, 232-239.	1.9	3
8	Quantification of Lung Perfusion Blood Volume in Dual-Energy Computed Tomography in Patients with Pulmonary Hypertension. Life, 2022, 12, 684.	2.4	0
9	Differences in extracellular fluid volume between acute heart failure patients with and without high systolic blood pressure. ESC Heart Failure, 2022, 9, 3358-3366.	3.1	4
10	Higher oxidized high-density lipoprotein to apolipoprotein A-I ratio is associated with high-risk coronary plaque characteristics determined by CT angiography. International Journal of Cardiology, 2021, 324, 193-198.	1.7	14
11	Electron Microscopy Revealed Massive Lipid Droplets in Cardiomyocytes in a Patient with Cardiogenic Shock Following a Fulminant Type 1 Diabetes Mellitus. International Heart Journal, 2021, 62, 197-200.	1.0	5
12	Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) ― Protocol of a Multicenter Randomized Control Trial ―. Circulation Reports, 2021, 3, 105-109.	1.0	3
13	Inhibitory effects of RAGE-aptamer on development of monocrotaline-induced pulmonary arterial hypertension in rats. Journal of Cardiology, 2021, 78, 12-16.	1.9	5
14	Efficacy of shear wave elastography for evaluating right ventricular myocardial fibrosis in monocrotaline-induced pulmonary hypertension rats. Journal of Cardiology, 2021, 78, 17-23.	1.9	2
15	Pathological and clinical effects of interleukin-6 on human myocarditis. Journal of Cardiology, 2021, 78, 157-165.	1.9	8
16	Preventative effects of bisoprolol transdermal patches on postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery: A subanalysis of the MAMACARI study. Journal of Cardiology, 2021, 78, 349-354.	1.9	3
17	Clinical outcomes of patients with isolated cardiac sarcoidosis confirmed by clinical diagnostic criteria. International Journal of Cardiology, 2021, 345, 49-53.	1.7	13
18	Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study. Heart Lung and Circulation, 2020, 29, 331-336.	0.4	9

#	Article	IF	Citations
19	Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet. Cardiovascular Diabetology, 2020, 19, 149.	6.8	11
20	Effects of Eicosapentaenoic Acid on Arterial Calcification. International Journal of Molecular Sciences, 2020, 21, 5455.	4.1	8
21	Medical and surgical management of a pulmonary hypertensive adult patient with unrepaired complex congenital heart disease: a case report. Journal of Congenital Cardiology, 2020, 4, .	0.5	0
22	Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e015103.	3.7	37
23	Effects of Bisoprolol Transdermal Patches for Prevention of Perioperative Myocardial Injury in High-Risk Patients Undergoing Non-Cardiac Surgery ― Multicenter Randomized Controlled Study ―. Circulation Journal, 2020, 84, 642-649.	1.6	7
24	New Appearance of Fragmented QRS as a Predictor of Ventricular Arrhythmic Events in Patients With Hypertrophic Cardiomyopathy. Circulation Journal, 2020, 84, 487-494.	1.6	8
25	Marked Reduction of Pulmonary Artery Pressure After Registration for Lung Transplantation Is Associated With Long-Term Survival in Patients With Pulmonary Arterial Hypertension ― Cohort Study ―. Circulation Journal, 2020, 84, 245-251.	1.6	6
26	Improvement of lung function and pulmonary hypertension after pulmonary aneurysm repair: case series. Pulmonary Circulation, 2019, 9, 1-4.	1.7	2
27	Emerging Role of Coronary Computed Tomography Angiography in Lipid-Lowering Therapy: a Bridge to Image-Guided Personalized Medicine. Current Cardiology Reports, 2019, 21, 72.	2.9	4
28	Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet. International Heart Journal, 2019, 60, 728-735.	1.0	23
29	Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification: Subanalysis of a prospective multicenter study. Atherosclerosis, 2019, 283, 1-6.	0.8	18
30	Role of smooth muscle cell p53 in pulmonary arterial hypertension. PLoS ONE, 2019, 14, e0212889.	2.5	26
31	The optimal amount of salt intake. Hypertension Research, 2019, 42, 752-753.	2.7	1
32	Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2019, 20, 5885.	4.1	16
33	Progression of pulmonary artery dilatation in patients with pulmonary hypertension coexisting with a pulmonary artery aneurysm. Journal of Cardiology, 2018, 71, 517-522.	1.9	10
34	Treat-and-repair strategy is a feasible therapeutic choice in adult patients with severe pulmonary arterial hypertension associated with a ventricular septal defect: case series. European Heart Journal - Case Reports, 2018, 2, yty033.	0.6	9
35	Association between Occupational Dysfunction and Metabolic Syndrome in Community-Dwelling Japanese Adults in a Cross-Sectional Study: Ibara Study. International Journal of Environmental Research and Public Health, 2018, 15, 2575.	2.6	8
36	Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0203046.	2.5	23

#	Article	IF	Citations
37	HCN4-Overexpressing Mouse Embryonic Stem Cell-Derived Cardiomyocytes Generate a New Rapid Rhythm in Rats with Bradycardia. International Heart Journal, 2018, 59, 601-606.	1.0	9
38	<i>TRPM4</i> Mutation in Patients With Ventricular Noncompaction and Cardiac Conduction Disease. Circulation Genomic and Precision Medicine, 2018, 11, e002103.	3.6	15
39	Effect of Intensive and Standard Pitavastatin Treatment With or Without Eicosapentaenoic Acid on Progression of Coronary Artery Calcification Over 12 Months ― Prospective Multicenter Study ―. Circulation Journal, 2018, 82, 532-540.	1.6	16
40	Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension. Journal of Cardiology, 2018, 72, 466-472.	1.9	30
41	Antibiotics Treatment for Cardiac Sarcoidosis: J-ACNES trial. The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders, 2018, 38, 34-39.	0.1	0
42	Epicardially placed implantable cardioverter-defibrillator for a child with congenital long QT syndrome. Journal of Arrhythmia, 2017, 33, 237-239.	1.2	4
43	Early and frequent defibrillator discharge in patients with cardiac sarcoidosis compared with patients with idiopathic dilated cardiomyopathy. International Journal of Cardiology, 2017, 240, 302-306.	1.7	23
44	Effects of reduction of pressure overload on right ventricular function in patients with Eisenmenger syndrome. Journal of Cardiology, 2017, 69, 739-740.	1.9	0
45	Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2017, 6, 48.	2.4	21
46	Suppression of Wnt Signaling and Osteogenic Changes in Vascular Smooth Muscle Cells by Eicosapentaenoic Acid. Nutrients, 2017, 9, 858.	4.1	18
47	Reverse Right Ventricular Remodeling After Lung Transplantation in Patients With Pulmonary Arterial Hypertension Under Combination Therapy of Targeted Medical Drugs. Circulation Journal, 2017, 81, 383-390.	1.6	20
48	Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice. PLoS ONE, 2017, 12, e0181009.	2.5	23
49	Construction of Mouseâ€Embryonicâ€Cellâ€Derived 3D Pacemaker Tissues by Layerâ€byâ€Layer Nanofilm Coati ChemNanoMat, 2016, 2, 466-471.	ng 2.8	0
50	Celsior preserves cardiac mechano-energetics better than University of Wisconsin solution by preventing oxidative stress. Interactive Cardiovascular and Thoracic Surgery, 2016, 22, 168-175.	1.1	3
51	Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16044.	4.1	9
52	Association between coronary artery calcification and left ventricular diastolic dysfunction in elderly people. Heart and Vessels, 2016, 31, 499-507.	1,2	17
53	Intratracheal Administration of Prostacyclin Analogue–incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2016, 67, 290-298.	1.9	26
54	Postprandial hyperlipidemia as a potential residual risk factor. Journal of Cardiology, 2016, 67, 335-339.	1.9	84

#	Article	IF	CITATIONS
55	Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size. Journal of Cardiology, 2016, 67, 177-183.	1.9	13
56	Prognostic significance of endothelial dysfunction in patients undergoing percutaneous coronary intervention in the era of drug-eluting stents. BMC Cardiovascular Disorders, 2015, 15, 102.	1.7	11
57	Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovascular Diabetology, 2015, 14, 83.	6.8	46
58	Enhancement of Spontaneous Activity by HCN4 Overexpression in Mouse Embryonic Stem Cell-Derived Cardiomyocytes - A Possible Biological Pacemaker. PLoS ONE, 2015, 10, e0138193.	2.5	33
59	Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vascular Health and Risk Management, 2015, 11, 265.	2.3	24
60	Delivery of Imatinib-Incorporated Nanoparticles into Lungs Suppresses the Development of Monocrotaline-Induced Pulmonary Arterial Hypertension. International Heart Journal, 2015, 56, 354-359.	1.0	31
61	Outcomes in Patients With High-Degree Atrioventricular Block as the Initial Manifestation of Cardiac Sarcoidosis. American Journal of Cardiology, 2015, 115, 505-509.	1.6	71
62	Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals $\hat{a} \in \text{``a randomized cross-over trial. Biomedicine and Pharmacotherapy, 2014, 68, 1071-1077.}$	5.6	48
63	Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovascular Diabetology, 2014, 13, 43.	6.8	54
64	Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovascular Diabetology, 2014, 13, 71.	6.8	21
65	Reverse remodeling of pulmonary arteries by high-dose prostaglandin I2 therapy: A case report. Journal of Cardiology Cases, 2014, 9, 173-176.	0.5	6
66	Cardiac erosion after catheter closure of atrial septal defect: Septal malalignment may be a novel risk factor for erosion. Journal of Cardiology Cases, 2014, 9, 134-137.	0.5	12
67	Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2013, 165, 499-505.	1.7	24
68	Different sizes of centrilobular ground-glass opacities in chest high-resolution computed tomography of patients with pulmonary veno-occlusive disease and patients with pulmonary capillary hemangiomatosis. Cardiovascular Pathology, 2013, 22, 287-293.	1.6	33
69	Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report. Cardiovascular Diabetology, 2013, 12, 8.	6.8	66
70	Increased Passive Stiffness of Cardiomyocytes in the Transverse Direction and Residual Actin and Myosin Cross-Bridge Formation in Hypertrophied Rat Hearts Induced by Chronic \hat{l}^2 -Adrenergic Stimulation. Circulation Journal, 2013, 77, 741-748.	1.6	26
71	A Decreased Level of Serum Soluble Klotho Is an Independent Biomarker Associated with Arterial Stiffness in Patients with Chronic Kidney Disease. PLoS ONE, 2013, 8, e56695.	2.5	167
72	Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2012, 159, 100-106.	1.7	54

#	Article	IF	CITATIONS
73	Elevated oxidative stress is associated with ventricular fibrillation episodes in patients with Brugada-type electrocardiogram without SCN5A mutation. Cardiovascular Pathology, 2011, 20, e37-e42.	1.6	10
74	Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis, 2011, 217, 486-491.	0.8	64
75	Circulating KCNH2 Current-Activating Factor in Patients with Heart Failure and Ventricular Tachyarrhythmia. PLoS ONE, 2011, 6, e19897.	2.5	5
76	Impact of Hypertriglyceridemia on Endothelial Dysfunction During Statin $\hat{A}\pm$ Ezetimibe Therapy in Patients With Coronary Heart Disease. American Journal of Cardiology, 2011, 108, 333-339.	1.6	32
77	Usefulness of acute pulmonary vasoreactivity test of sildenafil in treatment of portopulmonary hypertension. A case report. Journal of Cardiology Cases, 2011, 4, e31-e33.	0.5	1
78	Beta-Blockers and Oxidative Stress in Patients with Heart Failure. Pharmaceuticals, 2011, 4, 1088-1100.	3.8	52
79	Inhibitory Effects of Simvastatin on Platelet-derived Growth Factor Signaling in Pulmonary Artery Smooth Muscle Cells From Patients With Idiopathic Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2010, 55, 39-48.	1.9	27
80	Cytokine Reducing Effect of Azelnidipine in Human Peripheral Blood Mononuclear Cells. Biological and Pharmaceutical Bulletin, 2010, 33, 1148-1151.	1.4	4
81	Marked Hemodynamic Improvements by High-Dose Epoprostenol Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension. Circulation Journal, 2010, 74, 2200-2205.	1.6	59
82	Three-Dimensional Structure of Pulmonary Capillary Vessels in Patients With Pulmonary Hypertension. Circulation, 2010, 121, 2151-2153.	1.6	24
83	Atrial electrophysiological and structural remodeling in high-risk patients with Brugada syndrome: Assessment with electrophysiology and echocardiography. Heart Rhythm, 2010, 7, 218-224.	0.7	24
84	Altered nano/micro-order elasticity of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2010, 140, 102-107.	1.7	14
85	Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity. International Journal of Cardiology, 2010, 140, 328-335.	1.7	19
86	4-Hydroxy-2-nonenal Induces Calcium Overload via the Generation of Reactive Oxygen Species in Isolated Rat Cardiac Myocytes. Journal of Cardiac Failure, 2009, 15, 709-716.	1.7	42
87	Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. Cardiovascular Pathology, 2009, 18, 317-322.	1.6	14
88	Effects of Combined Treatment with Angiotensin II Type 1 Receptor Blocker and Statin on Stent Restenosis. Journal of Cardiovascular Pharmacology, 2009, 53, 179-186.	1,9	19
89	Are Adrenergic Receptor Blockers Effective or Contraindicated in Pulmonary Arterial Hypertension?. Circulation Journal, 2009, 73, 2212-2213.	1.6	2
90	Fulminant Eosinophilic Myocarditis Associated With Visceral Larva Migrans Caused by Toxocara Canis Infection. Circulation Journal, 2009, 73, 1344-1348.	1.6	37

#	Article	IF	CITATIONS
91	Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm, 2007, 4, 1292-1299.	0.7	166
92	Elevated Levels of Oxidative DNA Damage in Serum and Myocardium of Patients With Heart Failure. Circulation Journal, 2006, 70, 1001-1005.	1.6	90
93	Carvedilol Inhibits Proliferation of Cultured Pulmonary Artery Smooth Muscle Cells of Patients with Idiopathic Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2006, 47, 250-255.	1.9	39
94	Prednisolone Inhibits Proliferation of Cultured Pulmonary Artery Smooth Muscle Cells of Patients With Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 112, 1806-1812.	1.6	62
95	Relationship Between Oxidative Stress and Systolic Dysfunction in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2005, 11, 117-123.	1.7	63
96	Characterization of the Bone Morphogenetic Protein (BMP) System in Human Pulmonary Arterial Smooth Muscle Cells Isolated from a Sporadic Case of Primary Pulmonary Hypertension: Roles of BMP Type IB Receptor (Activin Receptor-Like Kinase-6) in the Mitotic Action. Endocrinology, 2004, 145, 4344-4354.	2.8	48
97	Epoprostenol Therapy Decreases Elevated Circulating Levels of Monocyte Chemoattractant Protein-1 in Patients With Primary Pulmonary Hypertension. Circulation Journal, 2004, 68, 227-231.	1.6	46
98	Micro-mechanical function analysis of reversible immortalized human aortic endothelial cells(Cellular & Tissue Engineering). The Proceedings of the Asian Pacific Conference on Biomechanics Emerging Science and Technology in Biomechanics, 2004, 2004.1, 81-82.	0.0	0
99	Direct Evidence for Increased Hydroxyl Radicals in Angiotensin II-induced Cardiac Hypertrophy through Angiotensin II Type 1a Receptor. Journal of Cardiovascular Pharmacology, 2003, 42, S67-S70.	1.9	28
100	Carvedilol Decreases Elevated Oxidative Stress in Human Failing Myocardium. Circulation, 2002, 105, 2867-2871.	1.6	259
101	Hepatitis C Virus Infection in a Patient With Dermatomyositis and Left Ventricular Dysfunction. Japanese Circulation Journal, 2000, 64, 617-618.	1.0	17
102	Manumycin A, Inhibitor of ras Farnesyltransferase, Inhibits Proliferation and Migration of Rat Vascular Smooth Muscle Cells. Biochemical and Biophysical Research Communications, 1999, 264, 915-920.	2.1	45
103	Inhibitory Effects of Antioxidants on Neonatal Rat Cardiac Myocyte Hypertrophy Induced by Tumor Necrosis Factor-α and Angiotensin II. Circulation, 1998, 98, 794-799.	1.6	483
104	Relationship Between Electrocardiographic Features and Distribution of Hypertrophy in Patients With Hypertrophic Cardiomyopathy. Japanese Circulation Journal, 1998, 62, 483-488.	1.0	9
105	Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	6